SOCIETY FOR CLINICAL TRIALS

VOLUME 31, #6 JULY 2020

INSIDE THIS ISSUE:

Registration opening soon for the SCT 2020 Virtual Annual Meeting

The 2020 SCT Program Task Force is pleased to share that content for the SCT Virtual Meeting for 2020 is in development and will be offered from September 1, 2020- April 30, 2021.

This virtual program will be available for free to all *current* SCT members. It includes the following content submitted for the 2020 SCT Annual Meeting which had to be sadly cancelled due to the COVID-19 pandemic:

- Recorded Presentations from Contributed presentations
- Webinars from Education Workshops and Tutorials
- Webinars from 10 Invited Sessions
- Recorded content including the Annual Business Meeting, Trial of the Year Presentation, Sylvan Green and Chalmers Awards Presentations.

Non-Members who wish to purchase this Educational Content can do so for the low price of just $170.

Thank you from the SCT Program Task Force

Susan Halabi, SCT President 2020-2021
Dean Fergusson, SCT Past President 2019-2020
Li Chen, SCT Treasurer
Domenic Reda, SCT Secretary
Jody Ciolino, Past Chair, Membership Committee
Dixie Ecklund, Past Co-Chair, Membership Committee
Jonathan Cook, 2020 Chair, Program Committee
Toshi Hamasaki, 2020 Co-Chair, Program Committee
Abby Shoben, Past Chair, Program Committee
Michael Grayling, 2020 Chair, Education Committee
Sin-Ho Jung, 2020 Co-Chair, Education Committee
Yves Rosenberg, Past Chair, Education Committee
Liz Garrett-Meyer, Past Chair, Communications Committee

THE PRELIMINARY PROGRAM FOR VIRTUAL INVITED SESSIONS AND EDUCATIONAL WORKSHOPS IS ON PAGE 2 OF THIS NEWSLETTER.

REGISTRATION OPENS FIRST WEEK OF AUGUST!

WATCH YOUR EMAIL INBOX FOR AN ANNOUNCEMENT

Or go to the SCT website for information about membership and registration for the SCT 2020 virtual meeting.

www.sctweb.org

SCT 2020-2021
Virtual Invited Sessions
and
Education Workshops

Dates, times, titles and presenters are subject to change

Title	Presenter(s)	Date Scheduled
Invited Session **Adjusting for prognostic baseline variables to improve precision and power in randomized trials.**	**Presenter** Michael Rosenblum	**September 30, 2020** **10:00am -11:00am ET**
Invited Session **The win ratio approach to composite endpoints**	**Presenters Information in Process**	**November 6, 2020** **12:00 pm – 1:00 pm ET**
Invited Session **Methodological advances in the conduct of behavioral clinical trials: an international behavioural trials network (ibtn) update**	**Presenters:** Simon Bacon Susan Czajkowski Kenneth Freedland Kim Lavoie	**December 14, 2020** **10:00am-11:30am ET**
Invited Session **The design and implementation of master protocols using examples from oncology clinical trials**	**Presenters:** Timothy Chen Amy Stark Shauna Hillman Sumithra Mandrekar Pamela Tenaerts	**January 12, 2021** **12:00pm-1:00pm ET**
Invited Session **Strategies to collaboratively manage protocol deviations in multi-site clinical trials**	**Presenters:** Dikla Blumberg Ashley Case Phoebe Gauthier Mitra Lewis Carmen Rosa Dagmar Salazar	**January 27, 2021** **12:00pm-1:30p ET**
Education Workshop **Using meta-analysis to combine results from clinical trials.**	**Presenters:** Yulia Marchenko Kristin MacDonald Houssein Assaad	**October 14, 2020** **12:30pm – 2:00pm ET**
Education Workshop **From Ideas to Efficacy: Designing & Optimizing Behavioral Treatments for Chronic Diseases**	**Presenters Information in Process**	**October 29, 2020** **2:00 pm– 3:30 pm ET**
Education Workshop **How to design and run an adaptive clinical trial: new resources and easy-to-use software**	**Presenters:** Munya Dimairo Michael Grayling Graham Wheeler	**November 11, 2020** **10:00am – 11:30am ET**
Education Workshop **Improving Quality and Controlling Costs in Clinical Trials Using Responsive Survey Design**	**Presenters:** James Wagner Brady West	**April 6, 2021** **11a ET – 12:30p ET**

Honoring our SCT Fellows

Mithat Gönen
SCT Fellows Committee Chair

The Society for Clinical Trials established the title of "Fellow of the Society for Clinical Trials (FSCT)" in 2005 to honor Society members who have made significant contributions to the advancement of clinical trials and to the Society.

On Wednesday July 8, 2020 we welcomed two new SCT Fellows, Leslie McClure and Lehana Thabane, who were elected in 2020. The virtual session honoring our new fellows was recorded and is available to SCT members at http://www.sctweb.org/members/webinars.cfm . Note you will need to log into the members areas to view the recording.

Leslie is Professor and Chair of the Department of Epidemiology and Biostatistics at Drexel University's Dornsife School of Public Health. Her diverse research interests include adaptive clinical trials, cardiovascular disease and environmental epidemiology. She has been an active member of SCT, organizing and participating in sessions at the Annual Meeting, serving and chairing various committees, including the Program Committee and the Communications Committee, and finally as a member of the Board of Directors. Being elected an SCT Fellow completes a hat trick for her, since she received similar honors from the American Heart Association and American Statistical Association.

Lehana is Professor and Interim Chair of Health Research Methods, Evidence, and Impact at McMaster University. He has played key roles in many practice-changing trials as statistician and as DSMB member, has been a pioneer in methodology for pilot studies and made significant contributions to clinical trial methodology. In addition to organizing sessions and presenting at SCT's Annual Meeting, he has been an Associate Editor for *Clinical Trials: Journal of the Society for Clinical Trials* and most recently he served as the Chair of the Nominations

SCT 2020 Fellows

Leslie McClure

Lehana Thabane

To date, 125 people have been selected as fellows.

Fellow	Inducted
Robert Annechiarico	2015
Peter Armitage	2006
Raymond P. Bain	2013
Gerald Beck	2013
Roy W. Beck	2010
Colin B. Begg	2012
Steve Belle	2018
William C. Blackwelder	2016
Jean-Pierre Boissel	2008
Marc Buyse	2008
Robert P. Byington	2013
Robert M. Califf	2015
Gregory Campbell	2016
Marion Campbell	2013
Paul L. Canner	2008
Kathryn Chaloner	2015
Ivan S.F. Chan	2011
Rick Chappell	2014
Li Chen	2019
Patricia Cleary	2014
Christopher Coffey	2015

Honoring our SCT Fellows (continued)

Fellow	Inducted
Joseph F. Collins	2009
Theodore Colton	2013
J. Richard Crout	2008
John Crowley	2016
Janet Darbyshire	2010
Barry R. Davis	2007
Clarence E. Davis	2010
Simon Day	2012
David L. DeMets	2006
Katherine Detre	2006
Kay Dickersin	2011
Marie Diener-West	2012
James J. Dignam	2019
Dennis O. Dixon	2010
Valerie Durkalski	2019
Fred Ederer	2006
William E. Elgie	2016
Jonas H. Ellenberg	2014
Susan S. Ellenberg	2006
Mark Espeland	2012
Scott R. Evans	2018
Frederick L. Ferris	2009
Lloyd D. Fisher	2006
Marian Fisher	2008
Ian Ford	2015
Mary A. Foulkes	2009
William T. Friedewald	2006
Lawrence Friedman	2007
Curt D. Furberg	2006
Jennifer Gassman	2009
Edmund A. Gehan	2009
Nancy L. Geller	2015
Michael Gent	2006
Stephen L. George	2010
Mithat Gonen	2019

Fellow	Inducted
Steven Goodman	2010
Sylvan B. Green	2007
Susan Halabi	2014
Robert J. Hardy	2011
Joerg Hasford	2008
Barbara S. Hawkins	2007
C. Morton Hawkins	2006
Daniel F. Heitjan	2017
Ronald Helms	2015
William G. Henderson	2008
Virginia J. Howard	2010
Kenneth E. James	2011
Theodore Karrison	2011
KyungMann Kim	2012
Genell L. Knatterud	2006
Heidi Krause-Steinrauf	2013
John M. Lachin	2006
Edward Lakatos	2014
Kuang-Kuo Lan	2009
Philip Lavori	2014
J. Jack Lee	2017
Kerry L. Lee	2017
Roger J. Lewis	2014
Anne S. Lindblad	2015
Frances F. LoPresti	2008
Ruth McBride	2008
Leslie Ain McClure	2020
Alison McDonald	2014
Eleanor McFadden	2012
Paul Meier	2006
Curtis L. Meinert	2006
Michele Melia	2015
Pamela Moke	2011
Thomas Erwin Moritz	2014
James D. Neaton	2009

Fellow	Inducted
John David Norrie	2015
Robert T. O'Neill	2013
Yuko Y. Palesch	2018
Mahesh K.B. Parmar	2015
Wendy R. Parulekar	2011
Peter Peduzzi	2010
Steven Piantadosi	2009
Stuart Pocock	2006
Sara Pressel	2009
Jeffrey Lynn Probstfield	2010
Domenic J. Reda	2012
Carol K. Redmond	2013
Frank W. Rockhold	2008
Yves D. Rosenberg	2017
Scott Rushing	2014
David L. Sackett	2009
Daniel Sargent	2012
Richard L. Schilsky	2017
Eleanor B. Schron	2007
Stan Shapiro	2010
Jay P. Siegel	2010
Robert J. Temple	2006
Michael Terrin	2018
Lehana Thabane	2020
Peter F. Thall	2014
Elizabeth Thom	2018
Barbara Tilley	2013
Joel I. Verter	2008
Marc Walton	2016
Julie Weston	2011
George W. Williams	2007
O. Dale Williams	2008
Janet Wittes	2006
Salim Yusuf	2008

Good Clinical Trials Collaborative Survey on Impacts of COVID-19 on Clinical Trials

Please Participate

Dear SCT Newsletter Readers,

The Good Clinical Trials Collaborative is led by Professor Martin Landray, Deputy Chief Investigator of the RECOVERY trial and Professor of Medicine and Epidemiology at the University of Oxford, and is supported by Wellcome, the Gates Foundation, and the African Academy of Sciences.

Our aim is to promote the development and adoption of proportionate GCP guidelines for randomized clinical trials, to enable timely, affordable & high quality assessment of health interventions.

We are currently running a global survey of clinical triallists, to gather their experiences of the impact of COVID -19 on clinical trials. We want to capture the innovative practices that have allowed some trials to continue, and the challenges and barriers that have impacted others.

We're looking for responses from triallists in any role, location, or organisation – as long as they've been involved in the delivery or management of a randomised clinical trial since January 2020.

More specifically, we are looking to extend our reach to hear diverse perspectives from triallists outside the UK (and from the US in particular).

Would you be able to support us by completing the survey?

The survey will be open until 5pm (BST) on Friday 7th August 2020 and should take respondents no longer than 15 minutes to complete. The link to the survey is here.

You can find more information about the survey or the Collaborative's wider efforts on our webpage, here.

SCT Honor's It's Long-Standing Members

(continued from June, 2020 issue)

Last issue we featured current members who have maintained continuous membership for at least 15 years. In this newsletter, we list current members who have held membership for 10 to 14 years. Among current members, some have held continuous membership since 1979! SCT would like to thank all of you distinguished and faithful members for your support of the Society. If your name is not listed below and you believe it should be, please contact our management office at info@sctweb.org

Many of our members renew their membership at the annual meeting. Since this year's meeting was cancelled due to the pandemic, we'd like to remind you that if you have not renewed your membership for this year there is still time. You can renew at http://www.sctweb.org/. Log in to the members only section with your membership credentials and renew today to continue your members benefits.

10-14 Years

Kaleab Abebe
Walter Ambrosius
Karla Ballman
Stephen Bernard
Marnie Bertolet
Laurent Billot
David Bristol
Chao-Yin Chen
Li Chen
Joan Chmiel
Jody Ciolino
Thomas Cook
Deborah Donnell
Jenny Donovan
Emily Dressler
Dixie Ecklund
Lynda Emel
Dean Fergusson
Ian Ford
Tim Friede
Mithat Gönen
Birgit Grund
David Hall
Emma Hall
Victoria Hench
Hai-An Hsu
Peter Jaehnig
Theodore Karrison
Shaji Kumar
Myeong Soo Lee
Bruce Levin
Roger Lewis
Robert Lindblad
Lukas Makris
Sumithra Mandrekar
Anne Meibohm
Stefan Michiels
Susan Murphy
Tony Panzarella
Charity Patterson
Letitia Perdue
Stephanie Pugh
Joseph Rausch
Yves Rosenberg
Reza Rostami
Kyle Rudser
Kevin Ruff
Eleanor Schron
Qian Shi
Mei-Chiung Shih
Yu Shyr
Nancy Silliman
Steven Snapinn
Nancy Stambler
Martin Stockler
Jeff Szychowski
Elizabeth Thom
Paul VanVeldhuisen
Nolan Wages
Michelle Walter
O. Williams
Anny Xiang
Haruko Yamamoto
Sharon Yeatts
Zhiying You

From the 22 Jul 2020 Newsletter

PROJECT UPDATES

Paper Discusses Development of CTTI Patient & Sponsor Prioritization Tool

In a new preprint manuscript, CTTI discusses the development and application of its

Prioritization Tool that can help patient groups and clinical research sponsors identify high-value opportunities to work together. The tool, developed through CTTI's Patient Groups & Clinical Trials work, was publicly announced last summer. For more information, please contact Zach Hallinan.

CTTI Publishes Results from Registry Trials Project

A new CTTI paper in *Therapeutic Innovation & Regulatory Science* identifies and describes the essential characteristics, processes, and practices required to embed and conduct registry-based clinical trials to support regulatory decision-making. The paper includes previously-released CTTI recommendations, suggested practices, and decision trees that help meet this need. These resources are designed to help clinical trial stakeholders effectively leverage patient registries to create high-quality, embedded clinical trials that benefit relevant patient populations. For more information, please contact Sara Calvert.

OTHER CLINICAL TRIALS NEWS & ANNOUNCEMENTS

FDA Draft Guidance on Developing Anti-Infective Drugs for the Pediatric Population

The FDA has issued a draft guidance titled Development of Anti-Infective Drug Products for the Pediatric Population. This guidance provides general recommendations on the development of anti-infective medicines for pediatric patients. The guidance addresses the timing of initiation of pediatric clinical studies, enrollment strategies, extrapolation of efficacy, and other considerations to help facilitate pediatric anti-infective drug product development. Comments are due by August 29.

FDA Office of Women's Health Seeks Your Feedback on Strategic Priorities

To maximize their ability to promote, protect, and advance the health of women, the FDA is seeking input on research priorities driven by data gaps and areas of unmet need; topics for education among consumers, health professionals, and other stakeholders; and outreach to women, especially underserved and diverse populations. They are also interested in proposed methods for acting on these priorities, such as collaborations and partnerships. Comments will be accepted until Sept. 8.

FDA Public Meeting on PROs and Medical Device Investigations

The FDA/CDRH is holding a virtual public meeting entitled "Patient-Reported Outcomes (PROs) and Medical Device Investigations: From Conception to Implementation" to discuss the benefits and challenges of incorporating the patient perspective in regulatory decision making using patient-reported outcome (PRO) instruments. The meeting will be held on Wednesday, September 30, 2020. Registration is required.

New Website from FDA/OCE's Project Patient Voice

The FDA launched Project Patient Voice, an initiative of the FDA's Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer trials for marketed treatments. While this patient-reported data has historically been analyzed by the FDA during the drug approval process, it is rarely included in product labeling and, therefore, is largely inaccessible to the public.

National Academies Publication On Clinical Trial Data Sharing

Late last year, the National Academies of Sciences, Engineering, and Medicine (NASEM) hosted a public workshop titled "Sharing Clinical Trial Data: Challenges and a Way Forward." The workshop followed the release of the 2015 IOM consensus study, Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk, and was designed to examine the current state of clinical trial data sharing and reuse since the report release. The following newly-released publication summarize presentations and points made at the workshop: Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward – Proceedings of a Workshop.

Recently Posted Notices & Guidance Documents

NOTICE

FDA Proposes New Rule on Reporting Requirement Under Right to Try Act

Today, the U.S. Food and Drug Administration published the proposed rule, Annual Summary Reporting Requirements Under the Right to Try Act, that when finalized, will implement a statutory requirement for sponsors and manufacturers to provide an annual summary to the FDA for any eligible investigational drug they provide to eligible patients under the Right to Try Act.

"The FDA is dedicated to achieving the goals that Congress set forth in the Right to Try Act, so that patients facing terminal conditions have another avenue to access investigational medicines," said Anand Shah, M.D., Deputy Commissioner for Medical and Scientific Affairs. "Today's proposed rule builds on the FDA's long-standing dedication to enhancing access for patients who are facing life-threatening diseases or conditions and our continued commitment to transparency."

The Right to Try Act, or the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017, provides a pathway for patients who have been diagnosed with life-threatening diseases or conditions who have tried all approved treatment options and who are unable to participate in a clinical trial, to access certain unapproved treatments. Ultimately, the sponsor or manufacturer who is developing the drug or biologic, not the FDA, is responsible for determining whether to make their product available to patients who qualify for access under the Right to Try Act.

Read More

DOCUMENTS

- 7/21/2020 - Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry: Draft Guidance for Industry
- 7/20/2020 - Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Commercial Manufacturers, Clinical Laboratories, and Food and Drug Administration Staff
- 7/20/2020 - Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use: Guidance for Industry and Food and Drug Administration Staff

Guidance Document Search

- Search all FDA official guidance documents and other regulatory guidance

National Institutes of Health
Office of Extramural Research

Extramural Nexus

From the July 2020 Edition

Open Mike

How We Handle Allegations of Sexual Harassment

By **Mike Lauer and Carrie Wolinetz**

If there are concerns that sexual harassment is affecting an NIH-funded project, we want to know about it. NIH takes the same rigorous approach to addressing allegations involving sexual harassment as we do other integrity issues. We have added a web page that highlights the detailed steps NIH takes when we receive notification of a concern. Continue reading →

Top Stories

Requirement for Electronic Submission of All Administrative Supplements

We just announced three important updates to our administrative supplement submission policies: effective immediately, NIH will begin accepting administrative supplement applications for multi-project awards electronically; and effective July 25, 2020, all supplement applications to existing single and multi-project awards must be submitted electronically and the streamlined submission method through the eRA Commons will be discontinued and replaced. Continue reading →

Signing Officials Can Access Overall Impact Scores and Summary Statements Starting June 24

Effective June 24, 2020, summary statements and overall impact scores for grant applications will be available on the eRA Commons Status Information screen to users with the signing official (SO) role. Currently, only principal investigators can view the scores and summary statements. Continue reading →

Upcoming Mandatory Submission of the Federal Financial Report (FFR) in the Payment Management System Beginning January 1, 2021

Beginning January 1, 2021, respective to NIH grant awards that require submission of an FFR, NIH grant recipients will be required to submit the SF-425 Federal Financial Report (FFR) in the Payment Management System (PMS) as opposed to the eRA Commons/FFR Module. Continue reading →

Is Your Application Responsive to the Goals of Your Selected Opportunity?

NIH just announced that, like Requests for Applications (RFAs), Program Announcements with special receipt, referral, and/or review considerations (PARs) and Program Announcements with set-aside funds (PASs) may now include criteria that would make an application non-responsive (i.e., outside the scope of the PAR/PAS). Continue reading →

Inclusion Reporting and FORMS-F

Recipients are now required to submit participant-level data on sex/gender, race, ethnicity, and age at enrollment in progress reports. Additionally, as of June 13, 2020 all post-submission updates in HSS must use the FORMS-F version. Continue reading →

You Ask, We Answer

Will NIH Accept Late Applications for New Awards From Applicants Affected by COVID-19?

NIH is taking a very flexible stance for applications submitted within the standard two week late policy. Applicants should include a cover letter with an explanation for the late submission. Continue reading →

What Is a "Rolling" Submission Date?

With "rolling" submission dates, we define the first and last days applications will be accepted and you pick the day between them to submit your application. This practice is not new, but it is more common with "emergency" or "urgent" funding opportunities meant to get funding to the community as quickly as possible to address a critical need (e.g., COVID-19 Funding Opportunities Specific to COVID-19). Continue reading →

The COMET Initiative brings together people interested in the development and application of agreed standardised sets of outcomes, known as 'core outcome sets' (COS). These sets represent the minimum that should be measured and reported in all clinical trials of a specific condition, but COS are also suitable for use in routine care, clinical audit and research other than randomised trials. The existence or use of a core outcome set does not imply that outcomes in a particular study should be restricted to those in the relevant core outcome set. Rather, there is an expectation that the core outcomes will be collected and reported, making it easier for the results of studies to be compared, contrasted and combined as appropriate; while researchers continue to explore other outcomes as well. COMET aims to collate and stimulate relevant resources, both applied and methodological, to facilitate exchange of ideas and information, and to foster methodological research in this area

The COMET Initiative will hold a series of webinars that will begin on the days which would have been the COMET VIII meeting.

8th October COMET VIII keynote speaker, Hywel Williams, (NIHR HTA Programme and Professor of Dermato-Epidemiology and Co-Director, Centre of Evidence-Based Dermatology, Queen's Medical Centre Nottingham University Hospitals NHS Trust) will kick off this exciting series talking about research waste.

9th October Paula Williamson and Sarah Gorst (University of Liverpool) will share with you what they see as key findings across the body of evidence about COS in the COMET database.

20th October Eleanor Perfetto (National Health Council) will focus on including patients in core outcome set work.

More details about forthcoming webinars will be announced as they become available.

http://www.comet-initiative.org/

Register for the COMET Webinars here

A Core Outcome Set for studies evaluating public health, primary and secondary care interventions for prevention **of COVID-19 transmission – the COS-COVID-P study**

Over recent months, COVID-19 has had, and continues to have, significant effects on morbidity and mortality around the world. Disease spread occurs in several ways, and reduction of spread is essential to reducing the morbidity and mortality associated with COVID-19. Whilst studies focus on mitigation of disease spread they include other issues relevant to the population of interest and type of intervention (e.g. educational outcomes in school studies, user acceptability of personal protective equipment (PPE) in secondary care). Evidence is gathering to describe effectiveness of interventions, but challenges with evidence synthesis remain due to inconsistent selection, measurement and reporting of outcomes (Chu et al, Lancet, 2020). In light of the ongoing epidemic, a recent Cochrane review evaluated PPE equipment for protection and reducing transmission of highly infectious diseases and recommended the development of a COS to standardise outcomes measurement in this field to enable better comparisons and synthesis across trials (Verbeek et al, Cochrane Database of Systematic Reviews, 2020, doi: 10.1002/14651858.CD011621.pub5). In an attempt to help tackle this for COVID-19 prevention studies, members of the COMET Management Group have recently agreed to work on the development of a core outcome set(s) for COVID-19 prevention studies. This may require development of a 'core' COS with the addition of specific COS ('modules') to tackle key areas of relevance, or a single COS may be sufficient.

Further information and development plans can be found at http://www.comet-initiative.org/Studies/Details/1594.

If you are interested in being involved in this work, please contact Sarah Gorst.

THANK YOU TO OUR CORPORATE SPONSORS!

Platinum Sponsors

Gold Sponsors

Gold Sponsor

ASTRAZENECA

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Gold Sponsor

GW BIOSTATISTICS CENTER

The GW Biostatistics Center has a 47 year history of leadership in practice-changing clinical trials and biostatistical methodology research. Center research has been recognized in reports to the US President and Congress and resulted in over 60 NEJM publications.

Gold Sponsor

FRONTIER SCIENCE FOUNDATION

Frontier Science Foundation is a not-for-profit research organization dedicated to the improvement of data management and statistical quality in clinical trials and medical research.

Silver Sponsors

Silver Sponsor

CYTEL

We provide unrivaled biostatistics and operations research knowledge to our customers. Our knowledge is available in the form of both software and services. This knowledge, supported by our trial implementation capabilities, is what makes us different. We are leaders in the design and implementation of adaptive clinical trials.

Silver Sponsor

JAEB CENTER FOR HEALTH RESEARCH

The Jaeb Center for Health Research was established in 1993 as a freestanding, nonprofit coordinating center for multi-center clinical trials and epidemiologic research. The Jaeb Center's focus is eye disorders or type 1 diabetes.

Silver Sponsor

EMMES

Emmes collaborates with clients to produce valued, trusted scientific research. We are passionate about making a difference in the quality of human health, and have supported more than a thousand studies across a diverse range of diseases since our formation in 1977.

Bronze Sponsor

Bronze Sponsor

JOURNAL OF CLINICAL MEDICINE

JCM (IF = 5.583) is an international scientific open access journal, providing a platform for advances in clinical practices, the study of direct observation of patients and general medical research. The journal is indexed by SCIE and PubMed.

Save the Dates - Upcoming SCT Annual Meetings

42nd Annual Meeting May 16-19, 2021

Chicago, Illinois USA



43rd Annual Meeting May 15-18, 2022

San Diego, California USA

Information About

SCT
SOCIETY FOR CLINICAL TRIALS

85 W. Algonquin Road
Suite 550
Arlington Heights, IL 60005
(847) 427-8010

Executive Director
Kevin Bragaw
Administrative Assistant
Angie Stark

info@sctweb.org
www.sctweb.org

@SCTorg

@sct.org